Table of Contents Author Guidelines Submit a Manuscript
Canadian Respiratory Journal
Volume 20, Issue 5, Pages 367-368
Focused Review

Tailored Therapy in Lung Cancer

George Rakovich1 and Lise Tremblay2

1Division of Thoracic Surgery, Hôpital Maisonneuve Rosemont, University of Montreal, Montreal, Canada
2Division of Respirology, Institut Universitaire de Cardiologie et de Pneumologie de Québec – Laval University, Quebec City, Quebec, Canada

Copyright © 2013 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Historically, all non-small cell lung cancers were essentially grouped together and considered to be a single disease. However, it is now recognized that non-small cell lung cancer actually comprises a genetically diverse group of tumours. This, in turn, affords a new opportunity for the development of effective treatments tailored to individual tumours and patients. Advances in molecular biology have made possible the development of drugs against specific molecular targets on cancer cells, most notably the tyrosine kinase inhibitors. The relevant literature and current practice guidelines are discussed. In addition, other related areas of active investigation, including tumour vaccines and pharmacogenetics, are briefly reviewed.